Literature DB >> 16782536

Dihydroarteannuin ameliorates lupus symptom of BXSB mice by inhibiting production of TNF-alpha and blocking the signaling pathway NF-kappa B translocation.

Wei-dong Li1, Yan-jun Dong, You-you Tu, Zhi-bin Lin.   

Abstract

The aim of this study was to investigate the mechanisms of action of Dihydroarteannuin (DHA), a semi-synthesized agent from the starting material artemisinin extracted from the Chinese Traditional Herbs Artemisia annua, on ameliorating the symptoms of lupus on BXSB mice. The concentration of TNF-alpha in the culture supernatant of the peritoneal macrophages and in the sera of BXSB mice was determined by the ELISA method. NF-kappaB protein expression and translocation were assayed by the EMSA method and laser confocal scanning microscopy method, respectively. IkappaB-alpha and NF-kappaB p65 protein expression were determined by the Western blot method. Renal tissue of the BXSB mice was prepared for assaying inhibitory activity of DHA on NF-kappaB, p65 and IkappaB-alpha protein expression in vivo. The peritoneal macrophages were prepared for analysis inhibitory effects of DHA on translocation of NF-kappaB into nuclear in vitro. We found that DHA strongly reduced the production of TNF-alpha in the culture supernatant of the peritoneal macrophages and in the sera of BXSB mice in vitro or in vivo. The results demonstrated that DHA decreased the expression of NF-kappaB subunit p65 protein and the activation of NF-kappaB in the renal tissue of BXSB mice in vivo. DHA effectively inhibited the nuclear translocation of NF-kappaB in peritoneal macrophages of BXSB mice in vitro. Furthermore, it was demonstrated that the degradation of IkappaB-alpha protein was significantly inhibited by DHA. These observations suggested that the inhibitory effects of DHA on TNF-alpha production may result from the block in the NF-kappaB signaling pathway upstream of IkappaB degradation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16782536     DOI: 10.1016/j.intimp.2006.03.004

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  37 in total

1.  The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine.

Authors:  Youyou Tu
Journal:  Nat Med       Date:  2011-10-11       Impact factor: 53.440

2.  Dihydroartemisinin supresses inflammation and fibrosis in bleomycine-induced pulmonary fibrosis in rats.

Authors:  Dongxia Yang; Wendan Yuan; Changjun Lv; Naie Li; Tongshen Liu; Liang Wang; Yufei Sun; Xueshan Qiu; Qiang Fu
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

Review 3.  Immune suppressive properties of artemisinin family drugs.

Authors:  Lifei Hou; Haochu Huang
Journal:  Pharmacol Ther       Date:  2016-07-10       Impact factor: 12.310

4.  Therapeutic effects of the artemisinin analog SM934 on lupus-prone MRL/lpr mice via inhibition of TLR-triggered B-cell activation and plasma cell formation.

Authors:  Yanwei Wu; Shijun He; Bingxin Bai; Luyao Zhang; Lu Xue; Zemin Lin; Xiaoqian Yang; Fenghua Zhu; Peilan He; Wei Tang; Jianping Zuo
Journal:  Cell Mol Immunol       Date:  2015-03-16       Impact factor: 11.530

5.  Effect of ω-3 polyunsaturated fatty acid on toll-like receptors in patients with severe multiple trauma.

Authors:  Chengzhi Yi; Xiangjun Bai; Jige Chen; Jiajun Chen; Jian Li; Peng Liu; Yiliu Liao
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-08-07

Review 6.  Artemisinins-a Promising New Treatment for Systemic Lupus Erythematosus: a Descriptive Review.

Authors:  Xiaozhen Mu; Chenchen Wang
Journal:  Curr Rheumatol Rep       Date:  2018-07-28       Impact factor: 4.592

7.  Artemisinin induces doxorubicin resistance in human colon cancer cells via calcium-dependent activation of HIF-1alpha and P-glycoprotein overexpression.

Authors:  C Riganti; S Doublier; D Viarisio; E Miraglia; G Pescarmona; D Ghigo; A Bosia
Journal:  Br J Pharmacol       Date:  2009-03-09       Impact factor: 8.739

8.  I kappa B alpha promoter polymorphisms in patients with systemic lupus erythematosus.

Authors:  Chia-Hui Lin; Shu-Chen Wang; Tsan-Teng Ou; Ruei-Nian Li; Wen-Chan Tsai; Hong-Wen Liu; Jeng-Hsien Yen
Journal:  J Clin Immunol       Date:  2008-05       Impact factor: 8.317

9.  Artemisinin suppresses sympathetic hyperinnervation following myocardial infarction via anti-inflammatory effects.

Authors:  Yongwei Gu; Xi Wang; Gang Wu; Xin Wang; Hong Cao; Yanhong Tang; Congxin Huang
Journal:  J Mol Histol       Date:  2012-08-26       Impact factor: 2.611

Review 10.  Artemisinins: their growing importance in medicine.

Authors:  Sanjeev Krishna; Leyla Bustamante; Richard K Haynes; Henry M Staines
Journal:  Trends Pharmacol Sci       Date:  2008-08-25       Impact factor: 14.819

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.